Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (The Motley Fool) What happened: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a precommercial pioneer...
Keep Reading →
April 2 - Market Movers, News - Comments
1. U.S. Stock Market: “The S&P 500 and the Nasdaq Composite hit fresh intraday records on Monday as a jump in oil prices to a two-week high...
Keep Reading →
May 15 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech - Comments
At Insider Monkey, we track more than 700 of the best hedge funds in the world and have developed various market-beating strategies over the years using...
Keep Reading →
March 16 - Hedge Funds, News - Comments
U.S indexes have opened lower this morning, as the trading week has kicked off with a plunge in global bonds courtesy of inflation fears. Those fears...
Keep Reading →
October 17 - Insider Trading, News - Comments
A couple of companies have had a tough twenty-four hours in the biotech space. One discontinuation, and another primary endpoint miss, has served up double...
Keep Reading →
October 7 - News, Stock Analysis - Comments
Many traders are watching crude futures today to see if WTI can break out of the $50 per barrel mark. On one hand, there will likely be strong resistance...
Keep Reading →
October 6 - Market Movers, News - Comments
Bridger Management, led by Roberto Mignone, has filed its 13F with the SEC for the current reporting period. Bridger Management is a New York-based...
Keep Reading →
August 18 - Hedge Fund Analysis, Hedge Funds, News - Comments
Biogen Idec Inc (NASDAQ:BIIB) is going back to the antisense well, teaming up with ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) for the fourth time in two...
Keep Reading →
September 11 - News - Comments
The health care sector has been one of the best performing sectors of 2013. Investors are excited about the sector, and they are willing to put their...
Keep Reading →
September 11 - News - Comments
Is Viropharma Inc (NASDAQ:VPHM) a good investment? If you were to ask many traders, hedge funds are seen as useless, old investment vehicles of an era...
Keep Reading →
August 28 - News - Comments
Here’s why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) might be a sell. Now, according to many market players, hedge funds are viewed as delayed,...
Keep Reading →
August 22 - News - Comments
Who’s crazy about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? If you were to ask many market players, hedge funds are seen as useless, outdated...
Keep Reading →
August 22 - News - Comments
Research into next-generation cholesterol drugs is picking up. Source: Wikimedia Commons. Once upon a time in a regulatory environment far, far away,...
Keep Reading →
August 21 - News - Comments
Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a safe stock to buy now? Hedge funds are turning bullish. The number of long hedge fund bets increased by...
Keep Reading →
August 6 - News - Comments
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view. The number of bullish...
Keep Reading →
August 6 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give...
Keep Reading →
August 6 - News - Comments
In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole. Now, this speculative growth market...
Keep Reading →
August 5 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling...
Keep Reading →
July 22 - News - Comments
According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year. This growth is due...
Keep Reading →
July 16 - News - Comments
If you thought the fireworks ended after the Fourth of July celebrations last week, think again. Plenty of pops and bangs were heard in the world of health...
Keep Reading →
July 15 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling...
Keep Reading →
July 15 - News - Comments
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Keep Reading →
July 15 - News - Comments
RNAi and RNA companies had a terrible time when they were abandoned by big pharmaceutical companies. The abandonment came from the fact that both types...
Keep Reading →
July 10 - News - Comments
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the...
Keep Reading →
July 8 - News - Comments
While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs. Here are three health...
Keep Reading →
July 8 - News - Comments
Shares of biotech Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have soared over 160% in the past year. The company’s a leader in developing drugs...
Keep Reading →
June 20 - News - Comments
About a third of American adults have high LDL cholesterol — that’s the bad kind — but less than half of adults with high LDL seek treatment...
Keep Reading →
June 18 - News - Comments
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has seen an increase in activity from the world’s largest hedge funds recently. To most traders, hedge...
Keep Reading →
June 11 - News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was in 13 hedge funds’ portfolio at the end of the first quarter of 2013. ARNA investors should pay attention...
Keep Reading →
June 10 - News - Comments
Small biotech companies have great investment potential if you can identify them properly. A small biotech with a differentiated treatment approach and...
Keep Reading →
April 24 - News - Comments
“There are many reasons for an insider to sell a stock, but only one to buy it: he expects to make money.” So goes the saying. Many investors...
Keep Reading →
March 7 - News - Comments
I have reviewed over 80 stocks as investment opportunities. Some were more successful than others; for example, Tesoro Corporation (NYSE:TSO) (best performer...
Keep Reading →
March 6 - News - Comments
